Christopher Haekang Chay MD

Oncology•Asheville, NC

Physician

Join to View Full Profile

551 Brevard RdAsheville, NC 28806
Phone+1 828-212-7021
Fax+1 828-232-8218

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 1999 - 2002
University of North Carolina HospitalsResidency, Internal Medicine, 1996 - 1999
University of North Carolina at Chapel Hill School of MedicineClass of 1996

Certifications & Licensure

NC State Medical License 1996 - 2025
MI State Medical License 1998 - 2003
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
ACTIVE_NOT_RECRUITING
PHASE3
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride Start of enrollment: 2011 Nov 15
Completed
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
ACTIVE_NOT_RECRUITING
PHASE3
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
COMPLETED
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small ce...
Ticiana A Leal, Yating Wang, Afshin Dowlati, Christopher H Chay, Yuanbin Chen
Cancer. 2025-06-15
1 citations
The effect of YOCAS©® yoga on cancer-related fatigue and quality of life in older (60+) vs. younger (≤ 59) cancer survivors: Secondary analysis of a nationwide, multic...
Evelyn Arana-Chicas, Po-Ju Lin, Umang Gada, Hongying Sun, Alisha Chakrabarti
Journal of Geriatric Oncology. 2024-11-01
10 citations
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Toby A Eyre, Nirav N Shah, Martin Dreyling, Wojciech Jurczak, Yucai Wang
Future Oncology. 2022-11-01

Press Mentions

Cancer Clinical Trials As-Care-Option Moves into Western North Carolina via Messino Cancer Centers & Sarah Cannon Research Institute PartnershipNovember 17th, 2020
Messino Cancer Centers Opens in Western North Carolina and Joins the American Oncology Network, LLCJanuary 7th, 2020
American Oncology Network : Messino Cancer Centers Strengthens Commitment to Patient Care with New PhysicianJune 4th, 2024